Skip to content

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03335553
Enrollment
122
Registered
2017-11-07
Start date
2017-11-15
Completion date
2021-07-02
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mediators of Inflammation

Brief summary

This is a study of experimental medication BMS-986235 in healthy subjects.

Interventions

Specified dose on specified days

OTHERPlacebo

Specified dose on specified days

Sponsors

Bristol-Myers Squibb
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients must be normal healthy volunteers as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations * Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive

Exclusion criteria

* Patients that are pregnant * Patient with any significant acute or chronic medical illness * Patient with a current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption * Patient with any surgery within 12 weeks of study treatment administration * Patient with any gastrointestinal surgery that could impact upon the absorption of study drug * Patient who donated blood to a blood bank or in a clinical study (except a screening visit) within 12 weeks of study drug administration (within 2 weeks for plasma only) * Patient who received a blood transfusion within 12 weeks of study drug administration Other protocol defined inclusion/

Design outcomes

Primary

MeasureTime frame
Number of serious adverse events (SAE)Approximately 30 days
Number of deathsApproximately 30 days
Number of adverse events (AE) leading to study discontinuationApproximately 30 days
Number of patients with clinically significant changes in ECG parameters, as defined by the investigatorApproximately 30 days
Number of patients with potentially clinically significant changes in vital signsApproximately 30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026